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Multidrug resistance (MDR) is a serious impediment to the
successful treatment of many human cancers. The phenothiazine,
chlorpromazine (CPZ), modulates P-glycoprotein (P-gp)-mediated
drug transport (Ford, 1996; Syed et al, 1998). We have shown that
CPZ and vinblastine (VLB) inhibit each other’s transport via P-gp
(Syed et al, 1998). However, the P-gp substrate colchicine (COL)
fails to inhibit P-gp-mediated CPZ transport (Syed et al, 1996),
indicating that the interaction of this drug substrate with P-gp
differs from that of VLB. 
The reversal of MDR by pharmacological modulators remains
poorly understood. Structure–function studies have failed to iden-
tify a common molecular requirement for reversal by structurally
and functionally dissimilar modulators. As with P-gp substrates,
hydrophobicity appears to be a consistent requirement for MDR
reversal by modulators, suggesting that their ability to partition
into the membrane is important (Zamora et al, 1988). 
Many modulators induce significant alterations in plasma
membrane properties that could affect the entry of drugs into cells
(Wadkins and Houghton, 1993). Membrane structure can also
affect P-gp’s catalytic cycle, since membrane-active compounds
can modulate P-gp-mediated drug transport (Saeki et al, 1991,
1992; Sinicrope et al, 1992; Callaghan et al, 1993; Regev et al,
1999). In addition, membrane-active compounds can affect the
binding of drug molecules to P-gp to different extents (Romsicki
and Sharom, 1999). 
Here we examine the effect of the membrane-active CPZ
on both the resistance and P-gp-mediated active transport of 
fluorescein-colchicine (FC), COL and VLB in the MDR cell line
CEM/VLB100. CPZ has different effects on both drug resistance
and transport with these 3 substrates. We propose that the effect of
CPZ on transport of P-gp substrates may depend on the particular
leaflet from which each substrate is transported. 
MATERIALS AND METHODS 
Cell culture 
The drug-sensitive parental human acute lymphoblastic leukaemia
cell line, CCRF-CEM (Foley et al, 1965), and its multidrug-
resistant subline, CEM/VBL100 (Beck et al, 1979), which was
selected for its resistance to 100 ng mL–1 VLB, were a kind gift
from Dr R Davey (Royal North Shore Hospital, Sydney). Cells
were grown as previously described (Bebawy et al, 1999). 
Cell proliferation assay 
The cytotoxicity profiles of VLB and COL in the presence and
absence of MDR reversal agents were assessed using the CellTiter
96® AQueous One Solution Cell Proliferation Assay (Promega,
USA). Exponentially growing cells were seeded into sterile 96-
well microtitre plates at a density of 5 × 104 cells/well. Cells were
treated with increasing concentrations of VLB or COL (Sigma,
USA) in complete RPMI-1640 medium in a final volume of 200
µ L in the presence or absence of 10 µ M verapamil (VER) (Sigma,
USA) or 2 µ M CPZ (Sigma, USA). The concentrations of reversal
agents chosen for these studies were the highest doses that had no
apparent lethal effects on the cells, as assessed from the effects of
VER and CPZ alone on cytotoxicity in the cell proliferation assay.
The highest non-lethal dose determined for each reversal agent
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was the same in both the CCRF-CEM and CEM/VLB100 cell lines
(data not shown). 
Control wells contained medium and cells without drugs. Plates
were incubated for 72 h at 37˚C in a humidified atmosphere with
5% CO2, after which cells were analysed for viability, 20 µ L of
AQueous One Solution was added to each well, and the cells incu-
bated for a further 4 h at 37˚C in a humidified atmosphere with 5%
CO2. Absorbance was read at 490 nm. 
Data are expressed as % cell viability ((average absorbance of
treated wells/average absorbance of control wells) × 100) versus
the test drug concentration. The IC50 values were defined as the
drug concentration that produced a 50% decrease in cell viability
following the 72 h treatment period. From this, the relative resis-
tance towards VLB and COL (IC50 of resistant subline/IC50 of
sensitive parental line) was calculated. Fold reversal in the pres-
ence of reversal agents (VER and CPZ) was calculated as the ratio
of IC50 in the absence of reversal agent/IC50 in the presence of
reversal agent. 
For the trypan blue dye exclusion assay, cells were seeded and
incubated as above with increasing concentrations of FC
(Molecular Probes, USA). Following the 72 h treatment period, 50
µ L trypan blue (0.5%) was added to 50 µ L cell suspension and the
cells enumerated using a haemocytometer. Data were expressed 
in terms of % cell viability ((average live cell counts of treated
wells/average live cell counts of control wells) × 100) versus FC
concentration, in order to determine the IC50 values. The relative
resistance towards FC for the CEM/VLB100 cell line and the fold
reversal in the presence of reversal agents were also calculated. 
Measurement of FC transport in inside-out 
plasma-membrane vesicles 
Inside-out plasma-membrane vesicles isolated from CCRF-CEM
and CEM/VLB100 cells were prepared as previously described
(Bebawy et al, 1999). Transport of FC into inside-out vesicles 
was determined as previously described (Bebawy et al, 1999).
Measurements of the transport of 150 nM FC ± CPZ were
conducted at 25˚C and 37˚C (0–10 µ M). The kinetics of 5 µ M
verapamil inhibition and 5 µ M CPZ activation of FC transport
were determined over a range of FC concentrations (0–1 µ M).
Initial rates of FC transport were calculated from the absolute
value of the slope relative to the amount of membrane vesicle
protein used in the reaction. 
Measurement of drug uptake into whole cells 
Initial rates of drug uptake into whole cells were measured using
the method described by Sirotnak et al (1986). Cells were
harvested and resuspended in uptake buffer (107 mM NaCl, 10
mM Tris-HCl, pH 7.4, 26.2 mM NaHCO3, 5.3 mM KCl, 1.9 mM
CaCl2, 1 mM MgCl2, 7 mM D-glucose) to a density of 2–4 × 107
cells ml–1 and used immediately. 
Drug influx at 37˚C was initiated upon the addition of either FC
or [3H]VLB at final concentrations of 50 µ M and 100 nM, respec-
tively. At given times, aliquots of cells were rapidly diluted into 2 ml
ice-cold phosphate-buffered saline (Gibco Life Technologies, 
Aus) to terminate the reaction. Samples were immediately washed
twice by centrifugation in the same buffer and the final pellet resus-
pended in 1 ml solubilising solution (0.5% (v/v) Triton X-100).
Radioactivity was quantified using a liquid scintillation counter.
Fluorescent samples were analysed using the read application of the
FLDM program in the Perkin Elmer LS-50 fluorimeter at excitation
and emission wavelengths of 492 nm and 519 nm, respectively. 
Data analysis 
IC50 values were calculated by fitting the plots of % cell viability
versus drug concentration to the inhibitory Sigmoid Emax model
(Meibohm and Derendorf, 1997) using MicroMath Scientific soft-
ware (version 2). An unpaired 2-tailed Student’s t-test was used for
statistical analysis between treatment groups. The a priori level of
significance was set at (P < 0.05). 
Initial rates of uptake of drug in inside-out vesicles and whole
cells were estimated by fitting plots of drug uptake versus time to
a polynomial or linear function, respectively, using Kaleidagraph
(version 3.0.4). This program uses the Levenberg–Marquardt algo-
rithm for nonlinear regression fits. Plots of initial rate of transport
versus concentration of drug were fitted to the Michaelis–Menten
equation by non-linear regression using Kaleidagraph (v 3.0.4). 
RESULTS 
Modulation of the cytotoxicity of P-gp substrates 
Dose–response cytotoxicity profiles for VLB, COL and FC were
established for both the drug-sensitive CCRF-CEM and drug-
resistant CEM/VLB100 cells ± the reversal agents, VER and CPZ. In
the absence of the reversal agents, the resistant CEM/VLB100 cells
displayed IC50 values of 710 ± 75 nM, 430 ± 50 nM and 14.2 µ M
for VLB, COL and FC, respectively (Figure 1). The IC50 values for
the CCRF-CEM cells were 1.5 ± 0.1 nM, 8.3 ± 1.2 nM and 1.02 ±
0.01 µ M for VLB, COL and FC, respectively (Figure 1). The rela-
tive resistance to VLB, COL and FC in the CEM/VLB100 cell line
was calculated to be 480-fold, 52-fold and 14-fold, respectively,
thus confirming that the CEM/VLB100 cell line was resistant to
VLB, COL and FC relative to the parental line. 
10 µ M VER reduced the IC50 for VLB and FC cytotoxicity of
CEM/VLB100 cells by 51-fold and 5.6-fold, respectively (Figures
1A, C) (P < 0.05). 10 µ M VER did not significantly alter the IC50
value for COL resistance (Figure 1B). VER had no significant
effect on the IC50 values for VLB, COL or FC in the parental
CCRF-CEM cell line (Figure 1A–C). 
2 µ M CPZ reduced the IC50 for VLB cytotoxicity in
CEM/VLB100 cells by 8-fold (Figure 1D). The same concentration
of CPZ, however, increased the IC50 value for COL by 3.6-fold
(Figure 1E). CPZ had no significant effect on the cytotoxicity
profile of FC (Figure 1F). CPZ had no significant effect on the
IC50 values for VLB, COL and FC cytotoxicity in the parental
CCRF-CEM cell line (Figure 1D–F). 
Effect on fluorescein-colchicine transport in inside-out
vesicles by verapamil and chlorpromazine 
The mechanism by which VER and CPZ modulated P-gp-
mediated transport of 150 nM FC was examined in inside-out vesicles
from CEM/VLB100 cells. VER inhibited the initial rate of 150 nM
FC transport into the CEM/VLB100 membrane vesicles in a dose-
dependent manner (Figure 2A, inset). Inhibition of FC transport in
CEM/VLB100 membrane vesicles occurred with a shift in both the
Km and Vmax, indicating that the inhibition was mixed (competi-
tive/non-competitive) (Figure 2A). 2000 M Bebawy et al
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CPZ activated 150 nM FC transport into the CEM/VLB100
membrane vesicles in a dose-dependent manner, with up to a 2.6-
fold activation at 10 µ M CPZ (Figure 2B, inset). The kinetics of
activation of FC transport by 5 µ M CPZ resulted from a 4-fold
decrease in Km. No effect on uptake by CPZ was observed in the
absence of ATP (data not shown). 
ATP-dependent FC transport in inside-out vesicles was 
temperature-dependent, and was 4.6-fold greater at 37˚C than at
25˚C (Figure 3A). The effect of CPZ on FC transport was exam-
ined at both 25˚C and 37˚C (Figure 3B). At 25˚C, increasing CPZ
maximally activated FC transport 8-fold at concentrations ≥ 4 µ M.
This contrasted with a maximum 2.6-fold activation observed at
37˚C (Figure 3B). 
Initial uptake rates of fluorescein-colchicine and
vinblastine in whole cells 
No significant difference in the initial rate of uptake of 50 µ M FC
was observed between the CCRF-CEM and CEM/VLB100 cells
(Table 1). In contrast, the initial uptake rate for 100 nM [3H]VLB in
CCRF-CEM cells was 10 times that of CEM/VLB100 cells (Table 1).
The reduction in initial rate of VLB uptake in CEM/VLB100 cells
compared to the CCRF-CEM cells was almost completely reversed
in the presence of 10 µ M VER (Table 1). The addition of VER
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Figure 1 The effect of VER and CPZ on VLB, COL and FC cytotoxicity in CEM/VLB100 cells. 5 × 104 CCRF-CEM (  , ∆ ) and CEM/VLB100 (   ,   ) cells were
exposed to increasing concentrations of VLB, COL and FC in the presence (   , ∆ ) and absence (  ,   ) of 10 µ M VER (A, B, C) or 2 µ M CPZ (D, E, F) for 72 h.
Results are expressed as % cell viability, which is equivalent to the number of viable cells in the presence of VLB, COL or FC divided by the number of viable
cells in the absence of these drugs (see Materials and Methods for details). (A) VLB ± VER; (B) COL ± VER; (C) FC ± VER; (D) VLB ± CPZ; (E) COL ± CPZ; 
(F) FC ± CPZ. The data represent the mean ± SEM P-glycoprotein-mediated cytotoxic drug resistance 2001
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DISCUSSION 
Drug resistance to the P-gp drug substrates, VLB, COL and 
the fluorescent COL derivative, FC, was assessed in the 
P-gp-expressing MDR cell line, CEM/VLB100, relative to the
parental drug-sensitive CCRF-CEM line. We have recently shown
FC to be a P-gp drug substrate using the inside-out membrane




















































































































































Figure 2 Effect of (A) VER and (B) CPZ on FC uptake by inside-out membrane vesicles from CEM/VLB100 cells at 37˚C. Initial uptake rates were determined
at the indicated concentrations of FC in the presence (   ) and absence (  ) of 5 µ M VER or CPZ, as described under Materials and Methods. The solid lines
represent the best fit to the data using the Michaelis–Menten equation. The calculated values of the parameters were as follows: (A) (   ) Vmax = 18.5 ± 9.1
pmoles mg–1 s–1, Km = 2 ± 1.3 µ M; (  ) Vmax = 2.9 ± 0.5 pmoles mg–1 s–1, Km = 0.5 ± 0.2 µ M. (B) (  ) Vmax = 16.3 ± 2.6 pmoles mg–1 s–1, Km = 2.7 ± 0.5 µ M; 
(   ) Vmax = 10.5 ± 0.8 pmoles mg–1 s–1, Km = 0.8 ± 0.1 µ M. Inset: Dose-dependent inhibition (A) and activation (B) of 150 nM FC transport by VER and CPZ,
respectively, in CEM/VLB100 inside-out membrane vesicles at 37˚C. Initial uptake rates were determined at the indicated concentrations of VER or CPZ, as
















































































Figure 3 Effects of temperature on FC initial uptake rate and CPZ activation
in inside-out membrane vesicles from CEM / VLB100 cells. Initial uptake rates of
150 nM FC were determined (A) at the indicated temperatures or (B) at
increasing concentrations of CPZ at 25˚C and 37˚C, as described under
Materials and Methods. Data are from one of 2–3 typical experiments 
Table 1 Initial uptake rates of 50 µ M FC, and 100 nM [3H] vinblastine (VLB)
in the presence and absence of 10 µ M verapamil (VPL) in CCRF-CEM and
drug-resistant CEM/VLB100 cells 
Cell line Condition Rate ± SEM
(pmoles 106 cells–1 s–1) 
FC 
CCRF-CEM 440 ± 12 
CEM/VLB100 580 ± 60 
[3H]VLB 
CCRF-CEM 0.004 ± 0.0002 
+VPL 0.004 ± 0.001 
CEM/VLB100 0.0004 ± 0.0001a
+VPL 0.003 ± 0.0004b
Initial uptake rates were determined as described in Materials and Methods. 
aP < 0.05 comparing the rate of [3H]VLB uptake in CEM/VLB100 to CCRF-
CEM control using the unpaired Student’s t-test (n = 3–4); bP < 0.05
comparing the rate of [3H]VLB uptake in the presence of verapamil (VPL) to
that in the absence of VPL using the unpaired Student’s t-test (n = 3–4). 2002 M Bebawy et al
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The multidrug transporter, P-gp, transports various drug substrates
differently. This is reflected by differences in the cooperativity of
transport of different drugs (Ayesh et al, 1996) and proposed differ-
ences in the plasma membrane site at which these substrates interact
with the drug transporter (Stein, 1997). Here we provide further
evidence for differences in the way substrates are transported and we
demonstrate selective modulation of P-gp-mediated MDR by a
reversal agent, depending on the type of drug transport. 
Whilst VER inhibited (to various degrees) drug resistance
to cell cytotoxicity of all the drug substrates examined
(Figure 1A–C), CPZ displayed both inhibition and enhancement of
drug resistance, depending on the drug substrate. As expected
from its inhibitory effects on P-gp-mediated [3H]VLB transport in
membrane vesicles (Syed et al, 1998), CPZ reversed VLB resistance
in intact CEM/VLB100 cells (Figure 1D). The same concentration
of CPZ, however, enhanced COL resistance (Figure 1E) and had
no effect on FC resistance in the same cells (Figure 1F). 
The effects of VER and CPZ on the P-gp-mediated transport of
FC in inside-out membrane vesicles from resistant cells were also
examined. The results obtained are consistent with resistance to
cytotoxicity in the CEM/VLB100 cells being, to a large part, depen-
dent on P-gp overexpressed in these cells. VER inhibited the initial
rate of FC transport in a dose-dependent manner (Figure 2A, inset),
consistent with its reversal of FC resistance in intact CEM/VLB100
cells (Figure 1C). The mixed (competitive/noncompetitive) kinetics
of inhibition of FC transport by VER (Figure 2A) suggest that the
inhibitor acts at a site distinct from the transport site. In contrast,
CPZ activated the transport of FC in a dose-dependent manner
(Figure 2B and inset). The activation is consistent with the failure
of CPZ to reverse COL or FC resistance in whole cells (Figure 1E,
F). The activation of transport is associated predominantly with an
increased affinity of the transporter for FC (Figure 2B). 
To determine if different substrates were localised within
different regions of the membrane bilayer, the initial uptake rates of
FC and VLB were examined in both the drug-resistant and drug-
sensitive cells. From kinetic analysis of the initial rates of uptake of
different P-gp drug substrates in whole cells, Stein (1997) proposed
that different drug substrates can preferentially interact with P-gp at
sites in different halves of the membrane bilayers from which they
are subsequently extruded (see Figure 4). Compounds whose initial
rate of uptake in resistant cells is reduced relative to their drug-
sensitive counterparts are proposed to be extruded from the outer-
membrane leaflet, prior to their penetration into the inner-membrane
leaflet of the plasma membrane (Figures 4C, D). Compounds
having the same initial rate of uptake in sensitive and resistant cells
must first accumulate in the inner leaflet before being effluxed by
P-gp (Figure 4A, B). Since the initial rate of FC uptake into the
drug-resistant CEM/VLB100 cells was the same as that observed in
the drug-sensitive cells (Table 1), according to Stein’s model P-gp-
mediated FC extrusion occurs from the inner membrane leaflet. In
contrast, the initial rate of VLB uptake was significantly lower in
the resistant cells than in the sensitive cells (Table 1), consistent
with the proposal that VLB is being extruded from the outer plasma
membrane leaflet. VER is able to overcome the reduced rate of
[3H]VLB transport in the resistant CEM/VLB100 cells (Table 1),
confirming the likely involvement of P-gp in the early extrusion
process. 
Whereas 5 µ M CPZ inhibited VLB transport (Syed et al, 1998),
it activated FC transport (Figure 2B). The overwhelming majority
of CPZ distributes to the inner membrane leaflet (Tenforde et al,
1978). Thus, the leaflet into which CPZ preferentially distributes is
the same as that in which we propose FC interacts with the drug
transporter (Table 1; Figure 4). Differential effects by CPZ on
pump activity have been demonstrated for the Na+/K+-ATPase:
CPZ was found to alter the affinity and the translocation rate of
cations interacting with the pump at the internal cationic site,
whilst having no effect on cations binding at the external cationic
site (Giraud et al, 1981). CPZ has been found to inhibit allosteri-
cally [3H]VLB transport in inside-out membrane vesicles (Syed 
et al, 1998). This is consistent with the fact that CPZ distributes
overwhelmingly to the inner membrane leaflet whilst as proposed,
VLB interacts with, and is transported by, P-gp at the outer leaflet
(Table 1; Figure 4). 
CPZ affects membrane properties (Sheetz and Singer, 1976) and
at concentrations > 2 µ M specifically interacts with the anionic
groups of phospholipids, such as phosphatidylserine, located
almost exclusively on the inner leaflet of the plasma membrane
(Zachowski and Durand, 1988). The activity of P-gp is dependent
on a cluster of 53–56 principally inner-leaflet phospholipids,
including phosphatidylserine, bound to the transporter (Sharom,
1997). We speculate that the activation by CPZ of P-gp transport of
FC results from an interaction between these bound lipids and CPZ.
The temperature-dependent effects of CPZ-induced activation on
FC transport, in which concentrations ≥ 4 µ M CPZ activated FC
transport 8 fold at 25˚C but only 2.6 fold at 37˚C (Figure 3B), may
reflect the temperature dependence of changes in the interaction
between CPZ and these bound lipids. This may lead to changes in
fluidity of the membrane surrounding the P-gp transport site and/or
decreased hydrophobic interactions, leading to changes in the





















Figure 4 Schematic diagram representing a model for P-gp-mediated drug
extrusion from the inner and outer lipid leaflet of the membrane bilayer
(Adapted from Stein, 1997). (A) A drug added to the extracellular medium at
a concentration So and which has a membrane permeability, P, will
accumulate within the cell to a concentration SI. The rate constant kI refers to
the rate constant for pumping out the drug from the inner leaflet of the
bilayer. At initial times (prior to significant accumulation of the drug within the
cell) rates of uptake will be independent of the presence or absence of the
pump; i.e., initial rates of uptake will be the same in both drug resistant (DR)
and drug sensitive (DS) cell lines (B). In (C), the pump serves to extrude
drug from the outer membrane leaflet with a rate constant KO. As a
consequence, at initial times the rate of uptake will be lower in DR cells
compared to DS cells (D)P-glycoprotein-mediated cytotoxic drug resistance 2003
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The present study has demonstrated that the modulation of
MDR by so-called reversal agents of P-gp is complex, and
depends on the site from which a particular substrate is transported
by P-gp in relation to the localisation in the membrane of the
modulator itself. Dissecting the details of these complex interac-
tions may aid in clinical treatment of MDR with reversal agents
selective for different cytotoxic drugs. 
ACKNOWLEDGEMENTS 
This research was supported by a Pharmacy Research Trust
Scholarship to MB and grants from the Sydney University Cancer
Fund. 
REFERENCES 
Ayesh S, Shao YM and Stein WD (1996) Co-operative, competitive and non-
competitive interactions between modulators of P-glycoprotein. Biochim
Biophys Acta 1316: 8–18 
Bebawy M, Morris MB and Roufogalis BD (1999) A continuous fluorescence assay
for the study of P-glycoprotein-mediated drug efflux using inside-out
membrane vesicles. Anal Biochem 268: 270–277
Beck WT, Mueller TJ and Tanzer LR (1979) Altered surface membrane
glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.
Cancer Res 39: 2070–2076 
Callaghan R, Stafford A and Epand RM (1993) Increased accumulation of drugs in a
multidrug resistant cell line by alteration of membrane biophysical properties.
Biochim Biophys Acta 1175: 277–282 
Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA and McCarthy RE (1965)
Continous culture of human lymphoblasts from peripheral blood of a child with
acute leukaemia. Cancer 18: 522–529 
Ford JM (1996) Experimental reversal of P-glycoprotein-mediated multidrug
resistance by pharmacological chemosensitisers. Eur J Cancer 32A: 991–1001 
Giraud F, Claret M, Bruckdorfer KR and Chailley B (1981) The effects of membrane
lipid order and cholesterol on the internal and external cationic sites of the Na+-
K+ pump in erythrocytes. Biochim Biophys Acta 647: 249–258 
Meibohm B and Derendorf H (1997) Basic concepts of pharmacokinetic
/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther
35: 401–413 
Regev R, Assaraf YG and Eytan GD (1999) Membrane fluidization by ether,
other anesthetics, and certain agents abolishes P-glycoprotein ATPase 
activity and modulates efflux from multidrug-resistant cells. Eur J Biochem
259: 18–24 
Romsicki Y and Sharom FJ (1999) The membrane lipid environment modulates
drug interactions with the P-glycoprotein multidrug transporter. Biochemistry
38: 6887–6896 
Saeki T, Shimabuku AM, Azuma Y, Shibano Y, Komano T and Ueda K (1991)
Expression of human P-glycoprotein in yeast cells—effects of membrane
component sterols on the activity of P-glycoprotein. Agri Biol Chem 55:
1859–1865 
Saeki T, Shimabuku AM, Ueda K and Komano T (1992) Specific drug binding by
purified lipid-reconstituted P-glycoprotein: dependence on the lipid
composition. Biochim Biophys Acta 1107: 105–110 
Sharom FJ (1997) The P-glycoprotein multidrug transporter: interactions with
membrane lipids, and their modulation of activity. Biochem Soc Trans 25:
1088–1096 
Sheetz MP and Singer SJ (1976) Equilibrium and kinetic effects of drugs on the
shapes of human erythrocytes. J Cell Biol 70: 247–251 
Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR and Brasitus TA (1992)
Modulation of P-glycoprotein-mediated drug transport by alterations in lipid
fluidity of rat liver canalicular membrane vesicles. J Biol Chem 267:
24995–25002 
Sirotnak FM, Yang CH, Mines LS, Oribe E and Biedler JL (1986) Markedly altered
membrane transport and intracellular binding of vincristine in multidrug-
resistant Chinese hamster cells selected for resistance to vinca alkaloids. J Cell
Physiol 126: 266–274 
Stein WD (1997) Kinetics of the multidrug transporter (P-glycoprotein) and its
reversal. Physiol Rev 77: 545–590 
Syed SK, Christopherson RI and Roufogalis BD (1996) Chlorpromazine transport in
membrane vesicles from multidrug resistant CCRF-CEM cells. Biochem Mol
Biol Int 39: 687–696 
Syed SK, Christopherson RI and Roufogalis BD (1998) Reversal of vinblastine
transport by chlorpromazine in membrane vesicles from multidrug-resistant
human CCRF-CEM leukaemia cells. Brit J Cancer 78: 321–327 
Tenforde TS, Yee JP and Mel HC (1978) Electrophoretic detection of reversible
chlorpromazine. HCl binding at the human erythrocyte surface. Biochim
Biophys Acta 511: 152–162 
Wadkins RM and Houghton PJ (1993) The role of drug-lipid interactions in the
biological activity of modulators of multi-drug resistance. Biochim Biophys
Acta 1153: 225–236 
Zachowski A and Durand P (1988) Biphasic nature of the binding of cationic
amphipaths with artificial and biological membranes. Biochim Biophys Acta
937: 411–416 
Zamora JM, Pearce HL and Beck WT (1988) Physical-chemical properties shared by
compounds that modulate multidrug resistance in human leukemic cells. Mol
Pharmacol 33: 454–462 